Abstract 775P
Background
Pathology-defined omental CRS after neoadjuvant chemotherapy (NACT) predicts survival outcomes in women with newly diagnosed FIGO stage IIIC/IV HGSOC. HRD-positive tumours have a superior response to PARPi therapy compared to HRD-negative tumours. We investigated the association between CRS and tHRD to assess CRS as a cost-free, potential biomarker for PARPi efficacy.
Methods
Eligible women included those with newly diagnosed FIGO stage IIIC/IV HGSOC treated with NACT and tested using Myriad’s myChoice® tHRD assay at The Christie Hospital between April 2021 and December 2023. Univariable and multivariable (MV) Cox proportional hazards models were developed to validate the association between survival outcomes and key clinical factors. The association between CRS3 (no/minimal residual tumour) and tHRD was assessed using the chi-squared test.
Results
315 women were included in the overall population (median age 67, range 36-91). 89 (28%) had FIGO stage IVB disease and 47 (15%) had a tBRCA1/2 mutation. 197 (63%) received 3-weekly carboplatin-paclitaxel. MV analysis of the overall population showed that undergoing primary cytoreductive surgery (yes vs. no) was prognostic (P
Conclusions
We found an association between tHRD and omental CRS in women with newly diagnosed FIGO stage IIIC/IV HGSOC treated with NACT and DPS. CRS should be evaluated in a prospective study as a biomarker of PARPi efficacy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Christie NHS Foundation Trust.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
793TiP - A phase III, randomized, open-label, multicenter study of sacituzumab tirumotecan (sac-TMT) monotherapy vs treatment of physician’s choice chemotherapy in patients with endometrial cancer who have received prior chemotherapy and immunotherapy: ENGOT-en23/GOG-3095/MK-2870-005
Presenter: Domenica Lorusso
Session: Poster session 02
795TiP - A first-in-human phase I study of LY4170156, an antibody-drug conjugate targeting folate receptor α (FRα)-expressing advanced solid tumors
Presenter: Isabelle Ray-Coquard
Session: Poster session 02
796TiP - Rationale and study design of the KOV-HIPEC-04: A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS)
Presenter: Junhwan Kim
Session: Poster session 02
797TiP - Tislelizumab combined with chemotherapy as neoadjuvant treatment for advanced endometrial cancer: A prospective, single-arm, open-label clinical study
Presenter: Zheng Hu
Session: Poster session 02
798TiP - Stereotactic radiotherapy alone or followed by niraparib for oligometastases or oligoprogression in ovarian cancer following PARP inhibitor therapy: SOPRANO trial
Presenter: Susana Banerjee
Session: Poster session 02
856P - Safety of neoadjuvant PARP inhibitor and immunotherapy in locally advanced HPV-negative head and neck squamous cell carcinoma (PRIME H&N Study)
Presenter: Luigi Lorini
Session: Poster session 02
857P - Safety and efficacy of neoadjuvant immunochemotherapy in patients with locally advanced head and neck squamous cell carcinoma: A prospective single-arm clinical trial
Presenter: Jing Yan
Session: Poster session 02
Resources:
Abstract
858P - Preoperative neoadjuvant chemoimmunotherapy for locally advanced head and neck squamous cell carcinoma patients: A prospective, single-arm, phase II clinical study
Presenter: Ping Han
Session: Poster session 02